Related Experiment Videos
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results
Insights
Aspirin, at both 300 mg and 1200 mg daily doses, showed similar efficacy in preventing vascular events after transient ischemic attack or minor stroke. The lower aspirin dose was less gastrotoxic and equally effective.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Transient ischemic attack (TIA) and minor ischemic stroke are critical conditions requiring effective long-term management.
- Antiplatelet therapy, particularly aspirin, is a cornerstone in preventing recurrent vascular events.
Purpose of the Study:
- To compare the long-term efficacy and safety of two different daily doses of aspirin (300 mg once daily vs. 600 mg twice daily) against placebo in patients with TIA or minor ischemic stroke.
- To assess the gastrointestinal toxicity and gender-specific responses to aspirin therapy.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 2435 patients.
- Patients were allocated to receive aspirin 600 mg twice daily, aspirin 300 mg once daily, or placebo.
- Follow-up extended to September 1986, with all vascular events and deaths recorded using an "intention to treat" analysis.
Main Results:
- No significant difference in efficacy was observed between the 300 mg and 1200 mg daily doses of aspirin.
- The lower dose of aspirin (300 mg) demonstrated reduced gastrointestinal toxicity compared to the higher dose.
- Combined aspirin groups showed a 15% reduction in the odds of major stroke, myocardial infarction, or vascular death compared to placebo, though not statistically significant.
- No significant difference in aspirin's response between males and females was detected.
Conclusions:
- Aspirin at 300 mg once daily is an effective and less gastrotoxic option for long-term prevention of vascular events in patients with TIA or minor ischemic stroke.
- The findings support the use of low-dose aspirin in this patient population, aligning with broader antiplatelet drug trial overviews.
- Further research may be needed to achieve statistically significant reductions in specific severe outcomes like disabling stroke or vascular death.
Abstract:
From 1979-85, 2435 patients with a transient ischaemic attack or minor ischaemic stroke were randomly allocated to receive long term "blind" treatment with aspirin 600 mg twice daily (n = 815), aspirin 300 mg once daily (n = 806) or placebo (n = 814). No patient was lost to follow up. The "intention to treat" comparison included all the serious vascular events and deaths which occurred before the end of the follow up period on 30 September 1986. There was no difference in efficacy between the 300 mg and 1200 mg daily doses of aspirin, but the lower dose was undoubtedly less gastrotoxic. Also, there was no definite difference in the response of males and females to aspirin. The odds of suffering a major stroke, myocardial infarction or vascular death were 15% less in the combined aspirin groups compared with the placebo group (95% confidence interval 29% reduction to 3% increase in odds) which is compatible with the continuing overview of all the similar trials of antiplatelet drugs where the relative reduction in odds was 25%. There was no statistically significant reduction in the likelihood of either disabling major stroke and vascular death or vascular death occurring.